Document:

FOrm
of Board Composition AGREEMENT

 

THIS BOARD COMPOSITION
AGREEMENT (this “Agreement”) is made and entered into as of this [●] day of [●], 2013,
by and among PharmAthene, Inc., a Delaware corporation (the “Company”), and each holder of the Company’s
Common Stock, $0.0001 par value per share (“Common Stock”), listed on Schedule A hereto (the “Stockholders”).

 

RECITALS

 

A.           The
Company, Taurus Merger Sub, Inc. (“Merger Sub”), Theraclone Sciences, Inc. (“Theraclone”)
and Steven Gillis, Ph.D., solely in its capacity as the representative of the Theraclone Stockholders are parties to that certain
Agreement and Plan of Merger, dated as of July 31, 2013 (the “Merger Agreement”), pursuant to which Merger Sub
is to be merged with and into Theraclone, with Theraclone being the surviving entity of such merger and thereby becoming a direct,
wholly owned subsidiary of the Company (the “Merger”); and

 

B.           In
connection with the Merger Agreement and as a condition to the consummation of the transactions contemplated thereby, including
the Merger, the Stockholders and the Company desire to enter into this Agreement to, among other things, obligate the Stockholders
to vote their respective shares of Common Stock for the election of the members of the board of directors of the Company (the “Board”)
in accordance with the terms of this Agreement.

 

NOW, THEREFORE, the
parties agree as follows:

 

1.           Voting
Provisions Regarding Board of Directors.

 

1.1           Size
of the Board. Each Stockholder agrees to vote, or cause to be voted, all Shares (as defined below) owned by such Stockholder,
or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary
to ensure that the size of the Board shall be set and remain at nine (9) directors. For purposes of this Agreement, the term “Shares”
shall mean and include any securities of the Company the holders of which are entitled to vote for members of the Board, including
without limitation, all shares of Common Stock, by whatever name called, whether now owned or subsequently acquired by a Stockholder,
however acquired, whether through stock splits, stock dividends, reclassifications, recapitalizations, similar events or otherwise.

 

1.2           Board
Composition. Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such
Stockholder has voting control, from time to time and at all relevant times, in whatever manner as shall be necessary to ensure
that at each annual or special meeting of stockholders of the Company at which an election of directors is held or pursuant to
any written consent of the stockholders of the Company, as follows:

 

(a)          effective
as of the Effective Time, to cause the board of directors of the Company to consist of nine (9) members, five (5) of whom shall
be current directors of the Company (each such person, a “PharmAthene Board Designee”), three (3) of whom shall
be the persons identified in Section 6.13 of the Theraclone Disclosure Schedule (each such person, a “Theraclone Board
Designee”) and the remaining seat shall be vacant;

 

(b)          to
cause the initial vacancy on the Company’s board of directors to be filled at Closing or as soon as possible thereafter by
a nominee (the “Fourth Theraclone Director”) approved by a majority of the then-serving Theraclone Board Designees
acting in their individual capacities and not in their capacities as directors;

 

    	 

    	 

    

 

(c)          to
cause one of the PharmAthene Board Designees (the “Resigning PharmAthene Board Designee”) to resign upon the
earlier of (i) such time as there has been a full settlement or a final, non-appealable resolution of that certain litigation matter
between the Company and SIGA Technologies, Inc. (the “Siga Determination Date”) and (ii) the second anniversary
of the Closing, but in no event prior to the first anniversary of the Closing (the “Resigning PharmAthene Board Designee
Resignation Date”);

 

(d)          to
cause all vacancies on the Company’s board of directors created by the cessation of service of any Theraclone Board Designee
to be filled by a nominee approved by the remaining Theraclone Board Designees;

 

(e)          to
cause all vacancies on the Company’s board of directors created by the cessation of service of any PharmAthene Board Designee
to be filled by a nominee approved by the remaining PharmAthene Board Designees;

 

(f)          to
cause fifty percent (50%) of the members of all committees of the PharmAthene Board of Directors to be filled by Theraclone Board
Designees and where a committee of the PharmAthene Board of Directors is comprised of an odd number of directors, the last director
shall be mutually agreed to by the PharmAthene Board Designees and Theraclone Board Designees that are members of such committee;

 

(g)          to
obtain the resignations, or to cause the removal without cause, of the directors identified on Section 6.13 of the PharmAthene
Disclosure Schedule as of the Closing Date;

 

(h)          to
obtain the resignation of the Resigning PharmAthene Board Designee on or before the Resigning PharmAthene Board Designee Resignation
Date.

 

The PharmAthene Board Designees, collectively
with the Theraclone Board Designees, may each be referred to as a “Designee,” and, collectively, as the “Designees.”

 

The Resigning PharmAthene Board Designee
shall be such person as may be determined by a majority of the PharmAthene Board Designees acting in their individual capacities
and not in their capacities as directors.

 

1.3          Removal
and Replacement of Board Members. Each Stockholder also agrees to vote, or cause to be voted, all Shares owned by such Stockholder,
or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary
to ensure that:

 

(a)          no
PharmAthene Designee elected as a director pursuant to this Agreement may be removed as a director unless such removal is directed
or approved by the remaining PharmAthene Designees;

 

(b)          no
Theraclone Designee elected as a director pursuant to this Agreement may be removed as a director unless such removal is directed
or approved by the remaining Theraclone Designees; and

 

(c)          any
vacancies on the Board created by the resignation, removal or death of (i) a PharmAthene Designee shall be filled by the person
designated by the remaining PharmAthene Designees, and (ii) a Theraclone Designee shall be filled by the person designated by the
remaining Theraclone Designees (and the corresponding definition of “PharmAthene Designee” or “Theraclone Designee”
shall be deemed to include such designated replacement director(s), as applicable).

 

    	- 2 -

    	 

    

 

All Stockholders agree to execute any written
consents required to perform the obligations of this Agreement, and the Company agrees at the request of any Stockholder to call
a special meeting of stockholders of the Company for the purpose of electing directors.

 

1.4           Proxy
Solicitation. If at any time the stockholders of the Company are entitled to vote on the composition of the Board, whether
at an annual or special meeting of the stockholders of the Company or pursuant to a written consent, the proposed list of directors
then to be voted on or consented to does not include all the PharmAthene Designees and the Theraclone Designees, then the Stockholders
agree to take all reasonable action to cause a proposal for the election of a Board comprising the PharmAthene Designees and the
Theraclone Designees to be submitted to a vote of the holders of the Company’s issued and outstanding voting stock, including
preparing and filing with the U.S. Securities and Exchange Commission a proxy statement and distributing the same to the stockholders
of the Company and engaging a proxy solicitor to advise on and assist with the solicitation of proxies.

 

1.5           No
Liability for Designation or Election of Directors.

 

(a)          The
parties acknowledge and agree that any direction or approval given hereunder by any PharmAthene Designee or Theraclone Designee,
including the designation of a person for election as a director of the Company, shall be given solely in such person’s individual
capacity, and not in such person’s capacity as a director, and, notwithstanding any conflict of interest, no PharmAthene
Designee or Theraclone Designee, nor any of their respective Affiliates (as defined below), shall have any liability as a result
of designating a person for election as a director for any act or omission by such designated person in his or her capacity as
a director of the Company, nor shall any Stockholder have any liability as a result of voting for any such designee in accordance
with the provisions of this Agreement. Nothing contained herein shall be deemed to require any person to vote in any particular
manner in his or her capacity as a member of the Board.

 

(b)          For
purposes of this Agreement, an individual, firm, corporation, partnership, association, limited liability company, trust or any
other entity (collectively, a “Person”) shall be deemed an “Affiliate” of another Person
who, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation,
any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing
that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person.

 

2.            Remedies.

 

2.1           Covenants
of the Company. The Company agrees to use its best efforts, within the requirements of applicable law, to ensure that the
rights granted under this Agreement are effective and that the parties enjoy the benefits of this Agreement. Such actions include,
without limitation, the use of the Company’s best efforts to cause the nomination and election of the directors as provided
in this Agreement.

 

2.2           Irrevocable
Proxy and Power of Attorney. Each party to this Agreement hereby constitutes and appoints as the proxies of the party and
hereby grants a power of attorney to the President of the Company, with full power of substitution, with respect to the matters
set forth herein, including without limitation, election of the Designees as members of the Board in accordance with Section 1
hereto, and hereby authorizes such person to represent and to vote, if and only if the party (i) fails to vote or (ii) attempts
to vote (whether by proxy, in person or by written consent) in a manner that is inconsistent with the terms of this Agreement,
all of such party’s Shares in favor of the election of the Designees. Each of the proxy and power of attorney granted pursuant
to the immediately preceding sentence is given in consideration of the agreements and covenants of the Company and the parties
in connection with the transactions contemplated by this Agreement and, as such, each is coupled with an interest and shall be
irrevocable unless and until this Agreement terminates or expires pursuant to Section 3 hereof. Each party hereto hereby revokes
any and all previous proxies or powers of attorney with respect to the Shares and shall not hereafter, unless and until this Agreement
terminates or expires pursuant to Section 3 hereof, purport to grant any other proxy or power of attorney with respect to any
of the Shares, deposit any of the Shares into a voting trust or enter into any agreement (other than this Agreement), arrangement
or understanding with any person, directly or indirectly, to vote, grant any proxy or give instructions with respect to the voting
of any of the Shares, in each case, with respect to any of the matters set forth herein.

 

    	- 3 -

    	 

    

 

2.3           Specific
Enforcement. Each party acknowledges and agrees that each other party hereto will be irreparably damaged in the event any
of the provisions of this Agreement are not performed by the parties in accordance with their specific terms or are otherwise
breached. Accordingly, it is agreed that each of the Company and the Stockholders shall be entitled to an injunction to prevent
breaches of this Agreement, and to specific enforcement of this Agreement and its terms and provisions in any action instituted
in any court of the United States or any state having subject matter jurisdiction.

 

2.4           Remedies
Cumulative. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and
not alternative.

 

3.            Term.
This Agreement shall be effective as of the date hereof and shall continue in effect until and shall terminate upon the earliest
to occur of (i) the fifth (5th) anniversary of the date hereof and (ii) the Siga Determination Date, but not sooner
than one year from the Closing.

 

4.            Sale
of Securities. Nothing contained herein shall be deemed to affect the right of any party hereto to sell, transfer, dispose
of, or otherwise deal in the Shares, provided that (a) in the case of any transfer to an Affiliate, the transferor shall take such
steps as may be appropriate to cause such transferee to be bound by the terms hereof, and (b) any transfer to a non-Affiliate shall
be free of this Agreement.

 

5.            Miscellaneous.

 

5.1           Successors
and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the parties hereto
and their respective successors and assigns. Nothing in this Agreement, express or implied, is intended to confer upon any person
or entity other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided herein.

 

5.2           Governing
Law. This Agreement shall be governed by, construed and enforced in accordance with, the internal law of the State of Delaware.

 

5.3           Definitions.
Capitalized terms used herein and not otherwise defined herein shall have the same meaning as in the Merger Agreement.

 

5.4           Counterparts.
This Agreement may be executed in counterparts, each of which will be deemed to be an original, but all of which, taken together,
will constitute one and the same instrument. A facsimile or electronic copy of a party’s signature printed by a receiving
facsimile machine or printer (including signatures in Adobe PDF or similar format) shall be deemed an original signature for purposes
hereof.

 

5.5           Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

    	- 4 -

    	 

    

 

5.6           Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt of: (a) personal delivery to the party to be notified; (b) when sent, if sent by electronic
mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day; (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (d) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight
prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the
Stockholders at their respective addresses as set forth on Schedule A hereto, or to such email address, facsimile number
or address as subsequently modified by written notice given in accordance with this Subsection 5.6. All communications shall be
sent to the Company at: [-------], Attention: General Counsel, with copies to Dentons US LLP, 1221 Avenue of the Americas,
New York, NY 10020-1089, Attention: Jeffrey A. Baumel, Esq. and Stephan J. Mallenbaum, Esq.

 

5.7           Consent
Required to Amend, Terminate or Waive. This Agreement may be amended or terminated and the observance of any term hereof may
be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument
executed by the Company and the Stockholders holding at least a majority of the Common Stock then held by Stockholders.

 

5.8           Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set
forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.

 

5.9           Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other
provision.

 

5.10         Entire
Agreement. This Agreement (including the Schedule hereto) constitutes the full and entire understanding and agreement among
the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter
hereof existing between or among the parties is expressly canceled.

 

5.11         Further
Assurances. At any time or from time to time after the date hereof, the parties agree to cooperate with each other, and at
the request of any other party, to execute and deliver any further instruments or documents and to take all such further action
as the other party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated
hereby and to otherwise carry out the intent of the parties hereunder.

 

    	- 5 -

    	 

    

 

5.12         Dispute
Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the Court of Chancery in
the State of Delaware or if (but only if) that court does not have subject matter jurisdiction to the jurisdiction of the United
States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based
upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement
except in the Court of Chancery in the State of Delaware or if (but only if) that court does not have subject matter jurisdiction
to the jurisdiction of the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert,
by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally
to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit,
action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that
this Agreement or the subject matter hereof may not be enforced in or by such court.

 

EACH OF THE PARTIES HERETO IRREVOCABLY
WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT.

 

[Signature Page Follows]

 

    	- 6 -

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Board Composition Agreement as of the date first written above.

 

	 	PHARMATHENE, INC.
	 	 
	 	By:	 
	 	 	Name: Eric I. Richman
	 	 	Title: Chief Executive Officer
	 	 
	 	STOCKHOLDERS:
	 	 
	 	 
	 	John M. Gill
	 	 
	 	 
	 	Brian A. Markison
	 	 
	 	 
	 	Joel McCleary
	 	 
	 	 
	 	Eric I. Richman
	 	 
	 	 
	 	Jeffrey W. Runge, M.D.
	 	 
	 	 
	 	Mitchel Sayare, Ph.D.
	 	 
	 	 
	 	Derace L. Schaffer, M.D.
	 	 
	 	 
	 	Steven St. Peter, M.D.

 

Signature
Page to Board Composition Agreement

 

    	 

    	 

    

 

	 	 
	 	Linda L. Chang
	 	 
	 	 
	 	Francesca Cook
	 	 
	 	 
	 	Wayne Morges, Ph.D.
	 	 
	 	 
	 	Jordan Karp, J.D.

 

Signature
Page to Board Composition Agreement

 

    	 

    	 

    

 

	 	CLIFFORD J. STOCKS
	 	 
	 	 
	 	Name:  Clifford J. Stocks
	 	 
	 	 
	 	STEVEN GILLIS, PH.D.
	 	 
	 	 
	 	Name:  Steven Gillis, Ph.D.
	 	 
	 	ARCH V ENTREPRENEURS FUND, L.P.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	ARCH VENTURE FUND V, L.P.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	HUTTON LIVING TRUST DATED 12/10/96
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	CANAAN VII L.P.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

Signature
Page to Board Composition Agreement

 

    	 

    	 

    

 

	 	HEALTHCARE VENTURES, LLC
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	DR. WENDYE ROBBINS
	 	 
	 	 
	 	Name: Dr. Wendye Robbins
	 	 
	 	 
	 	MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	MPM BIOVENTURES III, L.P.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	MPM BIOVENTURES GMBH & CO. BETEILIGUNGS KG
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	MPM BIOVENTURES III PARALLEL FUND, L.P.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	2

    	 

    

 

 

	 	MPM BIOVENTURES III-QP, L.P.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	3

    	 

    

 

SCHEDULE A

 

STOCKHOLDERS

 

	Name and Address	 	Number of Shares HeldFORM
OF Post-Closing Lock-Up Agreement

 

[Address]

 

Ladies and Gentlemen:

 

This Post-Closing Lock-Up
Agreement (this “Agreement”) is being delivered pursuant to that certain Agreement and Plan of Merger, dated
as of July 31, 2013, by and among PharmAthene, Inc., a Delaware corporation (“PharmAthene”), Taurus Merger Sub,
Inc., a Delaware corporation and a direct, wholly owned subsidiary of PharmAthene (“Merger Sub”) and Theraclone
Sciences, Inc., a Delaware corporation (“Theraclone”), and Steven Gillis, Ph.D., solely in its capacity as the
representative of the Theraclone Securityholders (the “Merger Agreement”). Capitalized terms used in this Agreement
and not otherwise defined herein shall have the meanings ascribed to them in the Merger Agreement. Pursuant to the terms of this
Agreement, the undersigned (“Stockholder”) is agreeing that all shares of PharmAthene Common Stock issued to
Stockholder as Merger Consideration in connection with the Merger, including shares held as of the Closing Date, and shares that
may be held in escrow (whether or not released from escrow) and including any shares issued in connection with any stock
split, stock dividend, recapitalization, reorganization, or the like (collectively, the “Lock-Up Shares”),
shall be subject to the restrictions and obligations as set forth in this Agreement.

 

As a material inducement
to PharmAthene’s willingness to enter into the Merger Agreement and for other good and valuable consideration, receipt and
sufficiency of which is hereby acknowledged, the undersigned agrees that, without the prior written consent of PharmAthene, the
undersigned will not, directly or indirectly offer, sell, pledge, contract to sell (including any short sale), grant any option
to purchase or otherwise dispose of any Lock-Up Shares or enter into any Hedging Transaction (as defined below) relating to the
Lock-Up Shares (each of the foregoing referred to as a “Disposition”) for a period from the date hereof until
such restrictions and obligations have lapsed, as provided in the following sentence. The restrictions and obligations set forth
in this Agreement shall lapse and be of no further force or effect as to:

 

(i) thirty-three percent
(33%) of the Lock-Up Shares (rounded up to the nearest whole share) on the six month anniversary of the Closing Date,

 

(ii) thirty-three percent
(33%) of the Lock-Up Shares (rounded up to the nearest whole share) on the nine month anniversary of the Closing Date, and

 

(iii) the balance of
the Lock-Up Shares (rounded up to the nearest whole share) on the first anniversary of the Closing Date (together with the dates
referenced in subsection (i)-(ii) above, the “Lapse Dates”).

 

The foregoing restrictions
are expressly intended to preclude the undersigned from engaging in any Hedging Transaction or other transaction which is designed
to or reasonably expected to lead to or result in a Disposition even if the securities would be disposed of by someone other than
the undersigned. “Hedging Transaction” means any short sale (whether or not against the box) or any purchase,
sale or grant of any right (including, without limitation, any put or call option) with respect to any security (other than a broad-based
market basket or index) that includes, relates to or derives any significant part of its value from the Lock-Up Shares.

 

    	 

    	 

    

 

Notwithstanding the
foregoing, the undersigned may transfer any or all of the Lock-Up Shares by (i) gift or to any member of the immediate family of
the undersigned or to any trust or partnership for the direct or indirect benefit of the undersigned or the immediate family of
the undersigned (including by will or intestate succession), provided that the transferee agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, (ii) to any
limited partners, members or stockholders of the undersigned, (iii) in transactions relating to shares of PharmAthene Common Stock
or other securities convertible or exercisable into shares of PharmAthene Common Stock acquired in open market transactions or
pursuant to employee benefit plans or incentive compensation plans after the execution of this Agreement (including, without limitation,
the sale of shares in a “same day sale” or “net exercise” in exercising an option grant or the sale of
shares in order to pay withholding taxes upon the vesting of restricted stock units); (iv) in transfers of shares of PharmAthene
Common Stock, or any security convertible into or exercisable or exchangeable for Common Stock, to the Company pursuant to agreements
under which the Company has the option to repurchase such shares or a right of first refusal with respect to transfers of such
shares; and (v) pursuant to a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common
Stock; provided, however, that in any such case it shall be a condition to the transfer pursuant to clauses (i) and (ii) above,
that the transferee execute an agreement stating that the transferee is receiving and holding the Lock-Up Shares subject to the
provisions of this Agreement, and there shall be no further transfer of such Lock-Up Shares except in accordance with this Agreement.

 

Without limiting the
restrictions or obligations herein, any Disposition by the undersigned shall remain at all times subject to applicable securities
laws.

 

The undersigned agrees
that PharmAthene may place an appropriate restrictive legend on the stock certificates representing the Lock-Up Shares issued to
the undersigned to indicate that such shares are subject to the terms of this Agreement. PharmAthene agrees that it will (or will
instruct the transfer agent for PharmAthene to) promptly remove such restrictive legend (a) upon the earlier to occur of (i) the
applicable Lapse Date (only with respect to the stock certificates representing such Lock-Up Shares that are no longer subject
to the restrictions and obligations of this Agreement) or (ii) the termination of this Agreement pursuant to its terms (with respect
to stock certificates representing all of the Lock-Up Shares) or (b) as otherwise expressly contemplated by this Agreement. The
undersigned agrees that PharmAthene may, and the undersigned will, with respect to any Lock-Up Shares, cause the transfer agent
for PharmAthene to note stop transfer instructions with respect to the Lock-Up Shares on the transfer books and records of PharmAthene.

 

The undersigned hereby
represents and warrants that the undersigned has full power and authority to enter into this Agreement. All authority herein conferred
or agreed to be conferred shall survive the death or incapacity of the undersigned and any obligations of the undersigned shall
be binding upon the heirs, personal representatives, successors and assigns of the undersigned.

 

Neither the execution
and delivery of this Agreement by the Stockholder nor the consummation of the transactions contemplated hereby will directly or
indirectly (whether with notice or lapse of time or both) (i) conflict with, result in any violation of or constitute a default
by the Stockholder under any mortgage, bond, indenture, agreement, instrument or obligation to which the Stockholder is a party
or by which it or any of the Lock-Up Shares are bound, (ii) violate any applicable Law to which the Stockholder, or any of the
Lock-Up Shares, may be subject, or (iii) result in the imposition or creation of any Lien upon or with respect to any of the
Lock-Up Shares; except, in each case, for conflicts, violations, defaults or Liens that would not individually or in the aggregate
be reasonably expected to prevent or materially impair or delay the performance by such Stockholder of its obligations hereunder.

 

If Stockholder is married,
he or she shall cause his or her spouse to execute and deliver to PharmAthene a Spousal Consent in the form of that attached hereto,
and should Stockholder hereafter become married, Stockholder shall promptly cause his or her spouse to execute and deliver to the
Company a Spousal Consent in such form.

 

    	2

    	 

    

 

This Agreement shall
terminate immediately and be of no further force or effect upon the earliest to occur of:

 

		(a)	immediately prior to the consummation of (i) any acquisition or purchase from PharmAthene by any
person (as defined in the Merger Agreement) or group (within the meaning of Section 13(d)(3) of the Securities Exchange Act of
1934, as amended (“Group”)) of a 20% or more interest in the total outstanding voting securities of PharmAthene
(other than as a result of the Merger), (ii) any merger, consolidation, business combination, share exchange or similar transaction
involving PharmAthene pursuant to which the stockholders of PharmAthene immediately preceding such transaction will hold securities
representing less than 80% of the total outstanding voting power of the surviving or resulting entity of such transaction (or PharmAthene
entity of such surviving or resulting entity) (other than as a result of the Merger), (iii) any sale, lease, exchange, transfer,
exclusive license or disposition of assets (including capital stock or other ownership interests in subsidiaries) representing
20% or more of the aggregate fair market value of the consolidated assets of PharmAthene and its subsidiaries taken as a whole,
(iv) any spin-off, spin-out, split-up, carve-out or similar event pursuant to which assets representing
20% or more of either the aggregate fair market value of the assets of PharmAthene as of the Closing Date or the business of the
PharmAthene as of the Closing Date will be transferred in one or more transactions or (v) the public
announcement of a third party regarding a “bear hug” letter sent to PharmAthene or the public announcement of a third
party regarding a tender offer for shares of PharmAthene Common Stock;

 

		(b)	immediately
                                                                                                following the launch of any tender
                                                                                                offer or exchange offer that if
                                                                                                consummated would result in any
                                                                                                person (as defined in the Merger
                                                                                                Agreement) or Group beneficially
                                                                                                owning securities representing
                                                                                                20% or more of the total outstanding
                                                                                                voting power of PharmAthene; or

 

		(c)	(i) the filing of a petition by or against PharmAthene under any chapter
of the Bankruptcy Reform Act, Title 11 of the United States Code, as amended or recodified from time to time, or under any similar
law relating to bankruptcy, insolvency or other relief for debtors, (ii) appointment of a receiver, trustee, custodian or liquidator
of or for all or any part of the assets or property of PharmAthene, (iii) the insolvency of PharmAthene, or (iv) the making of
a general assignment for the benefit of creditors by PharmAthene.

 

[Signature Page Follows]

 

    	3

    	 

    

 

	 	Very truly yours,
	 	 
	Dated: _____ ____, 2013	______________________________
	 	Print Name: ____________________
	 	 
	 	Acknowledged and Agreed:
	 	 
	 	PHARMATHENE, INC.
	 	 
	 	______________________________
	 	 
	 	Print Name: ____________________

 

    	4

    	 

    

 

STOCKHOLDER AGREEMENT & WRITTEN CONSENT
OF THE STOCKHOLDERS

– SPOUSAL CONSENT

 

I ____________________, spouse of ____________________,
have read and approve the foregoing Post-Closing Lock-up Agreement (the “Agreement”). In consideration
of the terms and conditions as set forth in the Agreement, I hereby appoint my spouse as my attorney in fact with respect to the
exercise of any rights and obligations under the Agreement, and agree to be bound by the provisions of the Agreement insofar as
I may have any rights or obligations in the Agreement under the community property laws of the State of Washington or similar laws
relating to marital or community property in effect in the state of our residence as of the date of the Agreement.

 

Date: ________________________________________

 

Signature of Spouse: ____________________________

 

Printed Name of Spouse: _________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]